Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.
Nucleic Acid Ther. 2022 Aug;32(4):300-311. doi: 10.1089/nat.2021.0105. Epub 2022 May 24.
We evaluated the potential of AGTR1, the principal receptor for angiotensin II (Ang II) and a member of the G protein-coupled receptor family, for targeted delivery of antisense oligonucleotides (ASOs) in cells and tissues with abundant AGTR1 expression. Ang II peptide ASO conjugates maintained robust AGTR1 signaling and receptor internalization when ASO was placed at the N-terminus of the peptide, but not at C-terminus. Conjugation of Ang II peptide improved ASO potency up to 12- to 17-fold in AGTR1-expressing cells. Additionally, evaluation of Ang II conjugates in cells lacking AGTR1 revealed no enhancement of ASO potency. Ang II peptide conjugation improves potency of ASO in mouse heart, adrenal, and adipose tissues. The data presented in this report add to a growing list of approaches for improving ASO potency in extrahepatic tissues.
我们评估了血管紧张素 II(Ang II)的主要受体和 G 蛋白偶联受体家族成员 AGTR1 在具有丰富 AGTR1 表达的细胞和组织中靶向递送反义寡核苷酸(ASO)的潜力。当 ASO 置于肽的 N 末端而不是 C 末端时,Ang II 肽 ASO 缀合物保持了强大的 AGTR1 信号和受体内化。Ang II 肽的缀合使 AGTR1 表达细胞中的 ASO 效力提高了 12-17 倍。此外,在缺乏 AGTR1 的细胞中评估 Ang II 缀合物,未发现 ASO 效力的增强。Ang II 肽缀合可提高 ASO 在小鼠心脏、肾上腺和脂肪组织中的效力。本报告中提供的数据增加了提高肝外组织中 ASO 效力的方法列表。